GeoVax Labs News

8-K: The Company Re-Convened a Special Meeting of Stockholders

Oct 16 16:33 ET

8-K: GeoVax Labs, Inc. Increased the Maximum Aggregate Offering Price of the Shares Issuable

Oct 15 16:50 ET

8-K: The Company Re-Convened a Special Meeting of Stockholders (The "special Meeting”) on October 1, 2024

Oct 1 17:21 ET

8-K: Entry into an underwriting agreement

Sep 25 17:25 ET

8-K: The Company Convened a Special Meeting of Stockholders on September 17, 2024

Sep 17 16:05 ET

S-1: General form for registration of securities under the Securities Act of 1933

Sep 6 16:10 ET

S-1: General form for registration of securities under the Securities Act of 1933

Sep 6 16:05 ET

8-K: GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Aug 30 16:18 ET

8-K: Placement Agency Agreement

Aug 21 16:21 ET

8-K: GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7 16:10 ET

S-1: General form for registration of securities under the Securities Act of 1933

Aug 6 17:14 ET

DEF 14A: Definitive information statements

Aug 1 16:18 ET

PRE 14A: Preliminary proxy statements relating to merger or acquisition

Jul 22 16:23 ET

8-K: GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market

Jul 12 16:08 ET

8-K: Current report

Jun 21 16:07 ET

8-K: GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company’s Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1

Jun 18 13:18 ET

S-1: General form for registration of securities under the Securities Act of 1933

Jun 7 16:09 ET

8-K: Current report

May 24 16:51 ET

GeoVax Labs | 8-K: Poll Results of GeoVax Labs Meeting

May 23 16:14 ET

8-K: Placement Agency Agreement

May 21 17:26 ET